Skip to main content
Future Journal of Pharmaceutical Sciences

Table 6 Statistical data obtained after application of the proposed methods to the tablet formulation

From: Novel approaches for determination of antiretroviral reverse transcriptase inhibitor agent in commercial dosage forms by using spectrofluorimetric, first derivative spectrophotometric, and HPLC methods

Dosage form

Method I

Method II

Method III

Cmean ± SD (mg/tablet)

% RSD

C.I.

Cmean ± SD (mg/tablet)

% RSD

C.I.

Cmean ± SD (mg/tablet)

% RSD

C.I.

Ternavir® tablet (135.58 mg Tenofovir/tablet)

138.05 ± 2.87

2.08

138.05 ± 3.57

137.71 ± 1.63

1.04

137.95 ± 0.98

136.44 ± 1.14

0.84

136.65 ± 1.42

tcal

1.93

2.13

1.68

fcal

6.36

  1. Cmean Mean of five determinations (n = 5); SD standard deviation; RSD relative standard deviation; CI confidence interval at 95% confidence limit (mg/tablet) (CI = %Recovery ± tSD/√n; t = theoretical t value (t value is 2.78 for n = 5), SD = standard deviation, n = number of determinations); tcal calculated t value; fcal calculated f value
Back to article page